Cleveland Heart Failure Summit 2026
Advanced Heart Failure · Amyloidosis · Cardiogenic Shock · Mechanical Support · AI · Precision Medicine
A comprehensive expert-led program focused on the latest advances in heart failure, cardiomyopathy and complex cardiovascular care, with 41 specialist-led video sessions.
From guideline-directed therapy to advanced heart failure support
Heart failure management is rapidly changing with new medications, devices, imaging techniques, metabolic therapies and advanced mechanical-support strategies.
This program reviews HFrEF and HFpEF, cardiac amyloidosis, cardiogenic shock, MCS, CKM syndrome, structural heart disease, arrhythmias, cardiomyopathy, remote monitoring, AI and precision medicine.
- Optimize guideline-directed medical therapy
- Manage HFrEF and HFpEF across different phenotypes
- Recognize advanced and end-stage heart failure earlier
- Select temporary and durable mechanical circulatory support
- Integrate AI, genetics, metabolic data and precision medicine
Seven Core Areas of Advanced Heart Failure Care
Heart Failure Therapeutics
GDMT, digitalis, vericiguat, metabolic interventions and emerging therapy for HFrEF and HFpEF.
Cardiac Amyloidosis
Nuclear imaging, TTR therapies, gene editing, AL amyloidosis and patient education.
Cardiogenic Shock & Support
Shock management, temporary MCS, ECMO configurations, LVAD and advanced HF referral.
Cardiomyopathy & Precision Medicine
Genetic cardiomyopathies, CD36 variants, sarcoidosis, cardio-oncology and gene-based therapies.
AI & Digital Health
Risk prediction, workflow integration, clinical decision support and remote monitoring.
Cardio-Kidney-Metabolic Care
CKM models, obesity, exercise, nutrition, population health and equitable access.
Structural Heart Disease & Arrhythmias
TAVR, surgical decision-making and catheter ablation for atrial fibrillation in HF.
What You Will Learn
Who Should Attend?
For healthcare professionals involved in diagnosis and management of heart failure and complex cardiovascular disease.
41 Expert-Led Sessions
Full session titles and durations from the supplied course content.
- 0110:41
Cardiac Amyloidosis: Expert Q&A on Diagnosis and Management
- 0218:53
ECMO Cannulation Strategy: Choosing VA, VAV, LAVA, and Other Configurations
- 0309:36
Heart Failure: Navigating Complex Clinical Intersections – Panel Discussion
- 0415:02
Cardiac Amyloidosis: Best Practices in Nuclear Imaging and Future Directions
- 0518:37
Evolutions in TTR Therapies: Matching Therapy to Phenotype
- 0612:29
Transthyretin Amyloidosis: Gene Editing Approaches
- 0716:18
AL Amyloidosis: Navigating Complex Diagnostic and Treatment Decisions (Case Based)
- 0818:23
Cardiac Amyloidosis: Educating Patients After a New Diagnosis
- 0921:15
Amyloidosis and the Musculoskeletal System
- 1015:36
Personalizing Care for LVAD Recipients
- 1115:14
Heart Allocation by Continuous Distribution: Are We Nearly There Yet?
- 1209:50
Cardiogenic Shock: Advanced Therapies – Panel Discussion
- 1340:18
Heart Failure: Practical AI Tools for Clinical Decision-Making
- 1417:13
Heart Failure: Which Patients Can Undergo CABG and Valve Surgery?
- 1515:45
Cardiogenic Shock: From Guidelines to Bedside
- 1617:05
Temporary MCS Devices: Right Device, Right Patient, Right Time
- 1714:54
HFpEF and Obesity: Tirzepatide Findings From the SUMMIT Trial and Substudies
- 1812:32
HFpEF: Clinical Insights From FINEARTS-HF, RE-DEFINE-HF, and Substudies
- 1915:29
Neuregulin and Other Regenerative Pathways in HFrEF
- 2021:08
Heart Failure: Top Five Practice-Changing Clinical Trials – Panel Discussion
- 2121:55
Heart Failure and CKM: Advancing Equitable Care
- 2219:12
HF Population Health: From Individual Care to Care Networks
- 2331:39
Reframing HF: Treating and Preventing the Syndrome, Its Causes, and Comorbid Conditions
- 2411:48
Heart Failure Care at Scale: Population Health Strategies – Panel Discussion
- 2516:03
The Role of Digitalis in HFrEF Therapeutics
- 2610:54
Vericiguat for HFrEF: Results From the VICTOR Trial
- 2715:39
HFrEF in the Device Era
- 2819:48
AI in HF: From Risk Prediction to Workflow Integration
- 2915:13
Gene Therapy for Cardiomyopathies: Why, Who, and How
- 3016:17
Implications of a CD36 Genetic Variant as a Cause of Cardiomyopathy
- 3118:02
Metabolic Health as a Therapeutic Target for HFrEF
- 3218:34
HF: Expert Q&A on AI, Emerging Therapies, and Future Directions
- 3314:34
Ambulatory PA Monitoring: Who, When, How?
- 3417:32
When GDMT Isn’t Enough: Recognizing Advanced HFrEF
- 3517:03
Heart Failure and Metabolic Disease: Expert Q&A
- 3618:34
CKM (Cardio-Kidney-Metabolic) Care Models: Practical Implementation
- 3719:07
HFpEF: Integrating Diet and Exercise Into Treatment
- 3817:31
Cardiac Sarcoidosis Across the EF Spectrum
- 3916:15
Cardio-Oncology in the Advanced HF Clinic
- 4016:36
Structural Heart Disease: Which Patients with AS and HFrEF Benefit Most from TAVR?
- 4116:57
Atrial Fibrillation in Heart Failure: Advances in Catheter Ablation and Arrhythmia Management
Course Director
Amanda Vest, MBBS
Course DirectorMBBS, MPH, FHFSA, FAHA, FACC
Build confidence across the full spectrum of modern heart failure care
Review HFrEF, HFpEF, amyloidosis, cardiogenic shock, ECMO, LVAD, transplantation, CKM care, cardiomyopathy, AI, remote monitoring, gene therapy, structural heart disease and arrhythmias.
Download Course
Reviews
There are no reviews yet.